Are you Dr. Tolar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
"# YPB-3"
New Haven, CT 06519Phone+1 203-785-4085
Summary
- Dr. Martin Tolar, MD is a neurologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and Massachusetts.
Certifications & Licensure
MA State Medical License 1999 - 2026
CT State Medical License 2002 - 2007
Publications & Presentations
PubMed
- Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.Sandar Aye, Gunilla Johansson, Christoph Hock, Lars Lannfelt, John R Sims
The Journal of Prevention of Alzheimer's Disease. 2025-01-01 - 1 citationsAPOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate inε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics.Susan Abushakra, Anton P Porsteinsson, Marwan Sabbagh, David Watson, Aidan Power
Alzheimer's & Dementia. 2024-08-13 - 172 citationsThe path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesisMartin Tolar, Susan Abushakra, Marwan N. Sabbagh
Alzheimer's & Dementia. 2020-11-01
Press Mentions
Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease ConferenceNovember 22nd, 2022- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s DiseaseSeptember 20th, 2022
- Alzheon Appoints Glenn Pauly as Head of CommercialSeptember 20th, 2022
- Join now to see all
